TRAF3 and plasma cell myeloma: Further autophagic degradation of TNF receptor associated factor (TRAF3), a key step in osteoclast differentiation, was inhibited by eliglustat, evidenced by TRAF3 action in restoring osteoclast formation in bone marrow cells in myeloma [170].